Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Usana Health Sciences Q3 2026 Results: Net Loss of $5.56M, Loss Narrows

USANA Health Sciences is transitioning to an omni-channel health and wellness model following the acquisitions of Hiya Health Products and Rise Wellness. The company reports a decline in net sales and active customers in its Core Nutritional direct-selling business, particularly in China, while facing macroeconomic pressures and volatile foreign currency fluctuations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue205.9213.7
Gross profit157.2164.9
Profit before tax-0.81.8
Net income-5.6-6.5
EPS (diluted, $ a share)$-0.30$-0.36

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-3.6%
Gross margin76.3%
Operating margin-0.7%
Source

10-Q filed with the SEC, NYSE: USNA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Usana Health Sciences Inc: key numbers

Share price
$13.54Close, Nov 16
Market cap
$250M
Shares outstanding
18.49MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Usana Health Sciences Inc

All →
4:11 PM ET 8-K
Financial Results

Usana Health Sciences Financial Results

USANA Health Sciences reported third quarter 2026 net sales of $206 million and a net loss of $5.6 million. While Core Nutritional active customers declined year-over-year, the company saw an 18% sequential increase in Hiya active monthly subscribers and generated $36 million in year-to-date free cash flow.

Term
Q3 2026

“As we continue our transformation to an omnichannel health and wellness company, our third quarter results were mixed, with meaningful improvement in some areas and results that fell short of our expectations in others.”

Kevin Guest, Chairman and Chief Executive Officer

“In Core Nutritional, rebuilding our active customer base is our top priority and our single largest growth lever.”

Kevin Guest, Chairman and Chief Executive Officer
4:36 PM ET 8-K
Loan & Debt

Usana Health Sciences $75M Debt Financing with Bank of America, N.A.

USANA Health Sciences entered into a first amendment to its $75 million revolving credit facility with Bank of America. The amendment modifies financial covenants, including a minimum consolidated EBITDA requirement of $100 million, and increases the annual limit for general asset disposals to $2.5 million. It also specifically permits the sale and potential leaseback of the company's real property in Sydney, Australia.

Value
$75M
Counterparty
Bank of America, N.A.
Term
through June 2030

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.